Radioimmunotherapy Targeting B7-H3
B7-H3
glioblastoma
pharmacodynamics
radionuclide drug conjugate
tumor microenvironment.
Journal
International journal of biological sciences
ISSN: 1449-2288
Titre abrégé: Int J Biol Sci
Pays: Australia
ID NLM: 101235568
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
07
2023
accepted:
01
08
2023
medline:
15
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
Radionuclide drug conjugates (RDCs) with antibodies serve as a novel approach for the treatment of malignant tumors including glioblastoma. However, RDCs require optimal antibodies to work efficiently. Hu4G4, a novel B7-H3-targeting humanized monoclonal IgG1 antibody, is highly specific for the human B7-H3 protein (a marker of tumor cells, including glioblastoma cells). Herein, we established
Identifiants
pubmed: 37705739
doi: 10.7150/ijbs.87763
pii: ijbsv19p4278
pmc: PMC10496502
doi:
Substances chimiques
Iodine-131
0
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4278-4290Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Mol Recognit. 2005 Jul-Aug;18(4):307-17
pubmed: 15952219
Cancer Immunol Immunother. 2012 Feb;61(2):215-221
pubmed: 22193987
Biomaterials. 2020 Oct;255:120190
pubmed: 32563943
Nat Immunol. 2016 Jul;17(7):797-805
pubmed: 27135602
J Mol Recognit. 2005 Jul-Aug;18(4):273-81
pubmed: 15997470
Mol Ther Oncolytics. 2019 Jul 23;14:279-287
pubmed: 31485480
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Neurologist. 2006 Nov;12(6):279-92
pubmed: 17122724
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Cancer Chemother Pharmacol. 2006 Jan;57(2):145-54
pubmed: 16001167
Nucl Med Mol Imaging. 2018 Aug;52(4):254-265
pubmed: 30100938
Cancer Sci. 2006 Jun;97(6):546-53
pubmed: 16734735
Int J Mol Med. 2018 Dec;42(6):3386-3394
pubmed: 30272348
Clin Cancer Res. 2012 Jul 15;18(14):3834-45
pubmed: 22615450
EMBO J. 2003 Oct 15;22(20):5551-60
pubmed: 14532127
Cancer Res. 2018 Apr 1;78(7):1820-1832
pubmed: 29363548
J Nucl Med. 2004 Aug;45(8):1366-72
pubmed: 15299063
Cell Death Dis. 2016 Feb 18;7:e2097
pubmed: 26890136
Expert Rev Clin Immunol. 2014 Jun;10(6):713-27
pubmed: 24746113
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209603
Cell Death Differ. 2017 Sep;24(9):1632-1644
pubmed: 28574504
Tumori. 2018 Jan-Feb;104(1):1-8
pubmed: 28967094
Mol Med. 2014 Apr 01;20:158-63
pubmed: 24618884
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
J Clin Oncol. 2017 Jul 20;35(21):2402-2409
pubmed: 28640706
Clin Transl Oncol. 2018 Jul;20(7):928-935
pubmed: 29119458
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
Neuro Oncol. 2014 Sep;16(9):1159-60
pubmed: 25096192
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35414591
Nat Rev Immunol. 2018 Apr;18(4):225-242
pubmed: 29151590
Neuropathol Appl Neurobiol. 2018 Feb;44(2):185-206
pubmed: 28767130
Appl Immunohistochem Mol Morphol. 2020 Nov/Dec;28(10):767-775
pubmed: 31714284
Nucl Med Biol. 2005 Jul;32(5):485-93
pubmed: 15982579
Nanomicro Lett. 2020 Nov 22;13(1):29
pubmed: 34138248
Mol Cancer Ther. 2022 Apr 1;21(4):635-646
pubmed: 35149548
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813267
J Exp Med. 2005 Dec 19;202(12):1691-701
pubmed: 16365148
Anticancer Drugs. 2005 Nov;16(10):1099-108
pubmed: 16222152
Mater Sci Eng C Mater Biol Appl. 2016 Oct 1;67:159-169
pubmed: 27287110
Oncoimmunology. 2018 Sep 5;7(12):e1501137
pubmed: 30524896
Am J Hematol. 2020 Jul;95(7):775-783
pubmed: 32243637
Br J Pharmacol. 2010 Nov;161(6):1219-37
pubmed: 20132208
Lancet Oncol. 2017 Jul;18(7):e414-e423
pubmed: 28677577
MAbs. 2013 Mar-Apr;5(2):297-305
pubmed: 23406896